R&D expenses were $52.6 million in the first six months of 2008, an 8%
decrease compared to $57.4 million in the same period of 2007. This
decrease was primarily due to termination of the INSPIRE Phase 3 trial of
Actimmune in March 2007. G&A expenses of $14.6 million in the first half of
2008 were approximately 12% lower than $16.6 million in the first six
months of 2007, reflecting headcount reduction and cost-control initiatives
following termination of the INSPIRE trial.
Second Quarter Highlights
-- Shionogi & Co., Ltd of Japan, which has rights to pirfenidone in
Japan, reported results of its Phase 3 study in Japan at the
American Thoracic Society meeting in Toronto on May 20. Following
the presentation, InterMune noted the following:
-- The baseline characteristics of patients enrolled in the
Shionogi Phase 3 trial and the InterMune Phase 3 CAPACITY
program are extremely similar.
-- The Shionogi Phase 3 trial confirmed the results reported by
Shionogi from their Phase 2 trial; notably a positive effect of
pirfenidone on the rate of decline in Vital Capacity over time
and an acceptable safety profile.
-- The number of patient dropouts in the Shionogi study was
consistent with that of other multi-center studies of other
compounds in IPF and the nature of the dropouts in the Shionogi
study may have underestimated the treatment effect of
-- The study conduct of CAPACITY is excellent and InterMune
expects to achiev
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved